OOIR: Observatory of International Research

Papers

(The median citation count of British Journal of Haematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Issue Information	129
e‐Posters	94
Don't forget cord blood in non‐remission acute myeloid leukaemia!	88
Issue Information	81
Immunophenotypic clustering in paediatric acute myeloid leukaemia	66
Issue Information	59
	56
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)	54
Would you like to take some more ruxolitinib after your fedratinib?	54
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho	50
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant	48
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial	47
Unveiling the responsible antigen in vaccine‐induced immune thrombotic thrombocytopenia	47
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia	47
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells	45
	44
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation	44
Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial	43
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation	43
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)	42
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia	42
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML	41
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma	38
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning	36
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203	36

Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews	36
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc	35
No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry	35
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)	35
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant	35
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma	35
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation	34
Indirect presentation of mismatched human leukocyte antigen ‐B associates with outcomes of cord blood transplantation	32
Population pharmacokinetics of high‐dose methotrexate and 7‐hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma	31
Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation	31
The impact of JAK2 ^V617F variant allele frequency in	29
Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients	29
Are there long‐term effects of combination therapy for newly diagnosed adults with ITP ?	28
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia	28
Chronic myelomonocytic leukaemia	28
Prolonged platelet hyperactivity after COVID‐19 infection	28
Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists	28
Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease	28
Immune thrombocytopenia (ITP) in pregnancy	27
The quiet brain injury in thrombotic thrombocytopenic purpura: Are we missing the warning signs?	26
	26
Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance	26
Flow cytometry‐guided ex vivo drug sensitivity testing informs venetoclax‐based therapy in acute undifferentiated leukaemia	26
Granulocyte colony‐stimulating factor may improve engraftment in adults with sickle cell disease undergoing non‐myeloablative haematopoietic stem cell transplantation	26
Health‐related quality of life reporting in randomized controlled trials of chimeric antigen receptor T‐cell therapy: A systematic review of dedicated publications	26
Screening for monoclonal gammopathy of undetermined significance is contraindicated	26
The oldest case of lymphoma? Insights from a XIII century fresco	26
Myelodysplastic syndrome associated‐haemophagocytic lymphohistiocytosis: A retrospective study of 15 cases in a single centre	25
Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis	25
Can we move beyond myeloablative conditioning ( MAC )? A comparison of MAC versus reduced intensit	25
The role of genetics in refractory immune thrombocytopenia	25
Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study	25
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia	25
Identification and management of preoperative anaemia in adults: A British Society for Haematology Guideline update	25
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey	24
Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British Osteo	24
How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax	24
Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH‐TC	23
Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium	23
A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction	23
Dynamic improvement of the treatment‐free remission prognostic score by prolonging MR4 duration in chronic myeloid leukaemia	23
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline	23
Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline	23
Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study	23
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms	23
Promises and challenges of artificial intelligence in haematological diagnostics	23
Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia	23
	22
Lower anti‐spike levels in B‐cell‐depleted patients after convalescent plasma transfusion suggest the need for repeated doses	22
Issue Information	22

A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complet	22
Issue Information	22
Factor VII deficiency: A cause of (or risk factor for) bleeding?	21
Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights	21
Novel transferrin gene mutations in four new cases of congenital Atransferrinaemia: Functional and diagnostic pathogenicity despite negative bioinformatics	21
Ganglioneuroblastoma with cannibalism in bone marrow	21
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma—Response	21
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia	21
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients	21
Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm	20
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B‐ALL in CR1 with no detectable minimal residual disease	20
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T‐ALL	20
Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia	20
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study	20
Another side of IgA neoplastic plasma cells	20
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study	20
Successful combined anti‐CD19 immunotherapy of relapsed acute lymphoblastic leukaemia in a child with Nijmegen breakage syndrome	20
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia	20
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease	20
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia	20
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post‐transplant clinical outcome in patients with aggressive ATL	20
Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper	19
Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings	19
An AI ‐based IHC quantification technique for assisting in the differentiation of	19
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study	19
A synonymous variant is unmasked in thalassaemia	19
Acute myeloid leukaemia with SRSF2 and BRAF mutations preceded by histiocytic proliferation in the bone ma	19
Mycosis fungoides and Sézary syndrome	19
A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma pat	19
A defined serum‐free culture system for human long‐term haematopoietic stem cells	19
Programmed cell death‐1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma	19
The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia	19
Clinical decision support to reduce unnecessary diagnostic testing for heparin‐induced thrombocytopenia	19
Antibody response and intra‐host viral evolution after plasma therapy in COVID ‐19 patients pre‐exposed or not to B‐cell‐depleting agents	18
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States	18
Erratum to: The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM	18
Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report	18
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis	18
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant	18
Concurrence of mixed cryoglobulinaemia and cold agglutinin disease, and the putative role for a stereotyped immunoglobulin light chain	18
Correction to ‘Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10	18
Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia	18
New cases expand the genotype, phenotype and therapeutic landscape of H syndrome	18
Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers	18
Correction to “Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib”LiM, LiuL, DingB, SongX, XiaA, HanY, et al. Refractory/relapse thrombocytope	18
	18
Distinct advantages for risk scoring models in patients with clonal cytopenia of undetermined significance	18
Methaemoglobinaemia: From pathophysiology to contemporary clinical management	17
Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring	17
Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study	17
Association of human leucocyte antigen loci with vaccine‐induced immune thrombotic thrombocytopenia: Potential role of the interaction between platelet factor 4‐derived peptides and MHC‐	17
BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real‐life study	17
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model	17
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome	17
Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma	17
Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series	17
Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials	17
Assessment of neurocognitive functioning in sickle cell disease and thalassaemia and the association with silent cerebral infarcts, cerebral haemodynamics and oxygen metabolism	17
Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state	17
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman‐like lymphadenopathies: A 20‐year retrospective analysis of clinical and pathological features	17
Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis	17
Fibrin‐associated large B‐cell lymphoma occurring in an ancient retroperitoneal schwannoma	17
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy	16
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study	16
Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma	16
Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload	16
Warm autoimmune haemolytic anaemia: Clinical considerations	16
Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation	16
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma	16
Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study	16
Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies	16
In a nutshell: Explaining joint and muscle bleeding in individuals with haemophilia A and B	16
Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis	16
Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma	16
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia	16
Bone marrow necrosis and fat embolism in critically ill patients with acute complications of sickle cell disease: A retrospective cohort study	16
Prognostic impact of FLT3‐ITD mutation on NPM1⁺ acute myeloid leukaemia patients and related molecular mechanisms	15
Laboratory practice on detection of antiphospholipid antibodies: UK NEQAS blood coagulation survey—2024	15
Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study	15
Issue Information	15

	15
Predict less, prevent more: A familiar mantra for sickle cell anaemia?	15
	15
A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures,	15
Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population‐based study from Ontario, Canada	15
NGS ‐based targeted sequencing guides risk‐adapted and molecularly targeted therapy decisions in multiple myeloma	15
Reed–Sternberg‐like cells in central nervous system relapse of diffuse large B‐cell lymphoma	15
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study	15
	15
Issue Information	15
Spurious thrombocytosis, red cell count and mean cell volume in a patient with thermal burns	15
DHCR7 drives AML development through the IL6 /	15
Inflammatory profile of lower risk myelodysplastic syndromes	15
External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registr	15
Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study	15
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response	15
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	15
	15
Issue Information	15
Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia	15
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients	15
Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies	15
Cauda equina syndrome secondary to extramedullary erythropoiesis in a transfusion‐dependent thalassemia patient following treatment with luspatercept: A case report	14
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study	14
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia	14
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients	14
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell‐associated neurotoxicity syndrome following chimeric antigen receptor T‐cell therapy	14
Survival prediction optimization of acute myeloid leukaemia based on T‐cell function‐related genes and plasma proteins	14
Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect	14
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3‐PBX1 positive acute lymphoblastic leukaemia	14
Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission	14
Chronic refractory immune thrombocytopenia in adolescents and young adults	14
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma	14
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis	14
Biochemical screening of glucose‐6‐phosphate dehydrogenase deficiency in borderline cases: Complementary inputs of standardization enzymes and comparison with genetic status	14
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan	14
The distribution and accumulation of the shortest telomeres in telomere biology disorders	14
How to discover the exceptional venetoclax responders in AML/MDS?	14
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance	14
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis	13
Dysplastic plasma cells in multiple myeloma	13
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study	13
Fetal and neonatal alloimmune thrombocytopenia: No evidence of systemic inflammation as a modulator of disease severity. Could placental inflammation be key?	13
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights	13
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation	13
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis	13
Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A prospective, multicentre, phase 2 clinical trial	13
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis	13
Contrasting impacts of pretransplant cytoreduction and post‐transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real‐world multicent	13
Predicting therapy‐related myeloid neoplasms after CAR‐T with the Clonal Haematopoiesis Risk Score (CHRS)	13
Decreased renal function predicts severe cytokine release syndrome after CAR ‐T‐cell therapy for large B‐cell lymphoma	13
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review	13
Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?	13
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in H	13
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation fr	13
Transient imaging changes accompany ‘spinal ICANS ’ following CAR T‐cell therapy for large B‐cell	13
Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells	13
‘Medical Haematology’ via systems‐based haematology	13
The usefulness of indium‐111 platelet scintigraphy beyond predicting efficacy of splenectomy	13
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study	13
Long‐term real‐world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all‐trans retinoic acid without chemotherapy—a retrospective, single‐centre study	13
	13
Clinical and neurophysiological aspects of peripheral neuropathy in patients with myelodysplastic syndromes	13
PF4 promotes CXCR3 ⁺ Tfh1 cell differentiation through STAT1	13
Further insights into the application of the TFR prognostic score (TPS) in CML patients attempting	13
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia	13
Single‐cell profiling of ineffective erythropoiesis in a mouse model of β‐thalassaemia intermedia	13
Effect of peptide‐binding motif on survival of HLA‐haploidentical transplantation with post‐transplant cyclophosphamide	13
Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy	13
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia	13
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas	13
Multiple myeloma with acicular crystalline inclusion bodies	13
Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorder	13
Prevalence of anti‐platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines—A systematic review and meta‐analysis	12
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications	12
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment	12
T‐cell‐based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic	12
Absence of femur induced by haemophilic pseudotumour	12
Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study	12
Drug‐induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data	12
Concurrent antiviral–immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B‐cell lymphoma: A multicentre cohort study	12
From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics	12
The BH3 ‐only protein NOXA is essential for apoptosis induction by BH3	12
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute my	12
Issue Information	12
Expression of Concern: Effect of insulin‐like growth factor 1 on PHA‐stimulated cord blood mononuclear cell telomerase activity	12
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 intern	12
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency	12
Oral iptacopan for paroxysmal nocturnal haemoglobinuria—First real‐world experience	12
Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia	12
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019	12
Molecular monitoring of myelodysplastic neoplasm: Don't just watch this space, consider the patient's ancestry	12
Association between vaccine‐induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?	12
Polatuzumab vedotin and CD79B : A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma	12
Risk factors for DIC in paediatric APL: Insights from the CCLG‐APL 2016 study	12